Vertex Pharma (VRTX) Tops Q2 EPS by 11c; Raises Outlook
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $508.34 -1.55%
EPS Growth %: -0.6%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -0.6%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $3.60, $0.11 better than the analyst estimate of $3.49. Revenue for the quarter came in at $2.2 billion versus the consensus estimate of $2.13 billion.
GUIDANCE:
Vertex Pharma raises FY2022 revenue to $8.6-8.8 billion, versus the consensus of $8.58 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
